Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders

Pelthos Therapeutics (NYSE American: PTHS) announced that its 2026 Annual Meeting of Stockholders will be held virtually on Tuesday, September 29, 2026 at 9:00 a.m. Eastern Time.

Rhea-AI Summary

Pelthos Therapeutics (NYSE American: PTHS) announced that its 2026 Annual Meeting of Stockholders will be held virtually on Tuesday, September 29, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on August 4, 2026 may vote at the meeting.

Pelthos expects to file its Notice of Annual Meeting and proxy statement in early August 2026. Because the 2026 meeting date is more than 30 days from the 2025 meeting anniversary, stockholder proposals under Rule 14a-8 must be received by August 3, 2026 for inclusion in the proxy materials.

Argus Jul 27 session 9 alerts

+6.44% close to close 5.1x rel. volume Open Argus

Details

News Market Reaction – PTHS

+6.1% Peak in 25 min

$90.09M Market Cap

On Jul 27, the first trading day after this news, PTHS closed 6.44% above the previous close. Argus tracked a peak move of +6.1% during that session. Our momentum scanner recorded 9 alerts for this stock that day. Relative volume reached 5.1x the daily average during tracking.

Data tracked by StockTitan Argus for the Jul 27 session.

Market Context

On Jul 27, the first trading day after this news, the stock closed 6.4% above the previous close. Pe...

Analysis

On Jul 27, the first trading day after this news, the stock closed 6.4% above the previous close. Pelthos previously recorded a 6.46% 24-hour gain after news_id 1057374, providing a positive historical comparator for this scheduling notice. The active S-3 shelf permits offerings of up to $200,000,000, representing a sourced financing risk.

Key Figures

Annual Meeting Date: September 29, 2026 at 9:00 a.m. Eastern Time Record Date: August 4, 2026 Meeting Date Change: More than 30 days +1 more

Annual Meeting Date

September 29, 2026 at 9:00 a.m. Eastern Time

2026 Annual Meeting of Stockholders

Record Date

August 4, 2026

Stockholder voting eligibility

Meeting Date Change

More than 30 days

Change from the anniversary of the 2025 Annual Meeting

Proposal Deadline

August 3, 2026

Rule 14a-8 stockholder proposals

Historical Context

5 past events · Latest: Jun 30

5 events

1. Jun 30

   Index inclusion

   24h Move

   -0.9%

   Russell index additions became effective following the 2026 Russell US Indexes reconstitution.

2. May 28

   Healthcare conference

   24h Move

   +2.6%

   CEO presentation and investor meetings were scheduled at Jefferies healthcare conference.

3. May 14

   Quarterly earnings

   24h Move

   +6.5%

   Q1 revenue growth and narrower net loss highlighted ZELSUVMI commercialization.

4. May 01

   Earnings date

   24h Move

   +0.0%

   Company scheduled first-quarter financial results and conference call for May 14, 2026.

5. Apr 14

   Biopharma symposium

   24h Move

   +0.0%

   CEO scheduled one-on-one investor meetings at Piper Sandler biopharma symposium.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

rule 14a-8, proxy statement, stockholders of record

3 terms

rule 14a-8 regulatory

"Stockholder proposals pursuant to Rule 14a-8 of the Securities Exchange Act"

Rule 14a-8 is a U.S. Securities and Exchange Commission regulation that lets eligible shareholders put proposals on a public company’s proxy ballot for an annual meeting, provided they meet basic ownership and filing requirements. It matters to investors because it creates a formal way to raise governance or strategic issues and force a company-wide vote—like getting an item onto the agenda of a neighborhood association meeting once you’ve lived there long enough—so shareholders can push for change or influence management decisions.

proxy statement regulatory

"The Company anticipates filing the Notice of Annual Meeting and proxy statement"

A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.

View in glossary

stockholders of record regulatory

"Stockholders of record as of the close of business on August 4, 2026"

Stockholders of record are the people or entities whose names appear on a company's official shareholder list on a specific cutoff date set by the company or its transfer agent; only those listed are entitled to receive dividends, vote at shareholder meetings, or participate in other corporate actions. Think of it like a guest list for an event: being on the list on the set day determines who gets the benefits and rights, so investors must own shares before the cutoff to qualify.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders virtually on Tuesday, September 29, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of the close of business on August 4, 2026 are entitled to notice of and to vote at the 2026 Annual Meeting. The Company anticipates filing the Notice of Annual Meeting and proxy statement in early August 2026.

The date of the 2026 Annual Meeting represents a change of more than 30 days from the anniversary of the Company’s 2025 Annual Meeting. Given the adjustment, stockholder proposals pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended, must be received in writing by the Company before the close of business on August 3, 2026 to be considered for inclusion in the Company’s proxy materials for the 2026 Annual Meeting.

About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI® (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The company’s portfolio of assets includes XEPI® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and XEGLYZE® (abametapir), a topical treatment for head lice. More information is available at https://pelthos.com/. Follow Pelthos on LinkedIn and X.

Contacts

Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is the Pelthos Therapeutics (PTHS) 2026 annual meeting of stockholders?

The Pelthos Therapeutics 2026 annual meeting will be held virtually on September 29, 2026 at 9:00 a.m. Eastern Time. According to Pelthos Therapeutics, this meeting date is more than 30 days from the anniversary of the 2025 annual meeting.

Who is eligible to vote at the Pelthos Therapeutics (PTHS) 2026 annual meeting?

Stockholders of record at the close of business on August 4, 2026 are eligible to vote. According to Pelthos Therapeutics, only these stockholders are entitled to notice of and to vote at the 2026 Annual Meeting.

How will the Pelthos Therapeutics (PTHS) 2026 annual meeting be conducted?

The Pelthos Therapeutics 2026 annual meeting will be held virtually. According to Pelthos Therapeutics, the online meeting is scheduled for September 29, 2026 at 9:00 a.m. Eastern Time, with additional access details expected in the proxy materials.

What is the deadline for Pelthos Therapeutics (PTHS) stockholder proposals for the 2026 annual meeting?

Stockholder proposals under Rule 14a-8 must be received by August 3, 2026. According to Pelthos Therapeutics, timely proposals may be considered for inclusion in the company’s proxy materials for the 2026 Annual Meeting.

When will Pelthos Therapeutics (PTHS) file its 2026 annual meeting proxy statement?

Pelthos Therapeutics anticipates filing its Notice of Annual Meeting and proxy statement in early August 2026. According to Pelthos Therapeutics, this filing will provide detailed information on the 2026 Annual Meeting and related voting matters.